King Pharmaceuticals KG Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $43.4M+27.5% | $34.05M+35.9% | $25.06M+199% | $8.37M+143% | $3.44M-10.5% | ||
| $39.66M+36.5% | $29.06M+60.3% | $18.13M+113% | $8.53M+84.3% | $4.63M-9.4% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | $132K+5.6% | $125K+2.5% | $122K+307% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is King Pharmaceuticals's revenue?
- King Pharmaceuticals (KG) generated $43.4M in revenue over the trailing twelve months, up 1160.2% year over year.
- Is King Pharmaceuticals profitable?
- King Pharmaceuticals reported $57.0M in net income over the trailing twelve months, a 131.4% net margin.
- What is King Pharmaceuticals's earnings per share?
- King Pharmaceuticals's diluted EPS over the trailing twelve months is $13.30.
- Where does King Pharmaceuticals's income statement data come from?
- Every line is extracted from King Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
